Answers are grounded in this paper and cite their sources.
In the last five years, six new antifolate drugs, all targeted towards thymidylate synthase (TS), have entered clinical studies. Most have evolved from highly focused and rational drug discovery initiatives, aimed at developing drugs with high specificity for TS. However, different design approaches led to each of these drugs possessing quite different chemical structures, and displaying unique biological profiles in vitro and in vivo. These different activities are largely a result of whether or not they interact with a saturable, carrier-mediated transport process (the reduced-folate carrier) and/or folylpolyglutamate synthetase. This has implications for both spectra of antitumour activity, toxicity and administration protocols. Each drug (Tomudex™, Thymitaq™, 1843U89, LY231514, AG331 and ZD9331) is at a different stage of clinical evaluation and early indications suggest that some of these may have promising activity in a number of tumour types. Indeed, Tomudex™ is now licensed for the palliative treatment of advanced colorectal cancer in several countries. If preclinical predictions prove correct, other members of this new family of TS inhibitors will find a place in cancer treatment protocols. Now that highly specific TS inhibitors are available, the full potential of TS as a chemotherapeutic target can be evaluated.
No takes yet. Share an insight, caveat, or question.
Jackman et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: